These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33546873)

  • 1. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
    Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
    Front Immunol; 2021; 12():712351. PubMed ID: 34504494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
    Sultanik P; Campani C; Larrey E; Campion B; Evain M; Roux C; Blaise L; Wagner M; Rudler M; Nault JC; Thabut D; Allaire M
    Dig Liver Dis; 2024 Sep; 56(9):1621-1630. PubMed ID: 38548580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Hou Y; Wu B
    Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
    [No Abstract]   [Full Text] [Related]  

  • 11. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.
    Özdirik B; Jost-Brinkmann F; Savic LJ; Mohr R; Tacke F; Ploner CJ; Roderburg C; Müller T
    Medicine (Baltimore); 2021 Jun; 100(24):e26377. PubMed ID: 34128898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    Scheiner B; Pomej K; Kirstein MM; Hucke F; Finkelmeier F; Waidmann O; Himmelsbach V; Schulze K; von Felden J; Fründt TW; Stadler M; Heinzl H; Shmanko K; Spahn S; Radu P; Siebenhüner AR; Mertens JC; Rahbari NN; Kütting F; Waldschmidt DT; Ebert MP; Teufel A; De Dosso S; Pinato DJ; Pressiani T; Meischl T; Balcar L; Müller C; Mandorfer M; Reiberger T; Trauner M; Personeni N; Rimassa L; Bitzer M; Trojan J; Weinmann A; Wege H; Dufour JF; Peck-Radosavljevic M; Vogel A; Pinter M
    J Hepatol; 2022 Feb; 76(2):353-363. PubMed ID: 34648895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
    Kelley RK; W Oliver J; Hazra S; Benzaghou F; Yau T; Cheng AL; Rimassa L
    Future Oncol; 2020 Jul; 16(21):1525-1536. PubMed ID: 32491932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety/efficacy of atezolizumab + bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma.
    Moriguchi M; Okuda K; Horiguchi G; Kataoka S; Seko Y; Yamaguchi K; Nishimura T; Fujii H; Mitsumoto Y; Miyagawa M; Kirishima T; Okishio S; Hara T; Ishikawa H; Nagao Y; Jo M; Ishii M; Tanaka S; Yamauchi N; Mitsuyoshi H; Nakajima T; Taketani H; Yano K; Arai M; Umemura A; Itoh Y
    Liver Int; 2024 Aug; 44(8):1751-1761. PubMed ID: 38838097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab- and bevacizumab -induced encephalitis in a patient with advanced hepatocellular carcinoma: a case report and literature review.
    Sagong M; Kim KT; Jang BK
    J Cancer Res Clin Oncol; 2024 Aug; 150(8):397. PubMed ID: 39180675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
    Castet F; Willoughby CE; Haber PK; Llovet JM
    Clin Cancer Res; 2021 Apr; 27(7):1827-1829. PubMed ID: 33472912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.